Tag: haemodialysis access
Venova Medical announces US$30 million Series B financing and appointment of...
Venova Medical has announced the initial closing of a US$30M Series B funding round. Catalyst Health Ventures and a leading medical device company co-led...
Xeltis receives IDE approval from US FDA for haemodialysis vascular access...
Xeltis has announced that it has gained approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) submission to...
New algorithm aims to provide clearer guidance on high AV access...
At the most recent American Society of Diagnostic and Interventional Nephrology (ASDIN) annual scientific meeting (23–25 February 2024, New Orleans, USA), Gerald Beathard (University...
Haemodialysis access session offers routes to improved outcomes for patients
At the 2023 VEITHsymposium (14–18 November, New York, USA), the final day featured a dedicated programme entitled “Improving outcomes in haemodialysis access”, which was...
“One-minute check” and cannulation simulator promise improvements to dialysis access
It was not just presentation sessions that featured during the Sunday morning of the American Society of Diagnostic and Interventional Nephrology (ASDIN) 19th Annual...
Live from ASDIN: HeRO or zero? An upper extremity alternative for...
The American Society of Diagnostic and Interventional Nephrology (ASDIN)’s 2023 meeting (17–19 February, Orlando, USA) has seen its second day start with style, as...
The aXess vascular graft: Potentially fulfilling a major unmet clinical need...
This advertorial is sponsored by Xeltis.
An de Vriese (Bruges, Belgium), who is playing a leading role in an ongoing European trial investigating the aXess...
Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access...
Xeltis announced today the initiation of a pivotal trial with the “first-ever” restorative synthetic haemodialysis access grafts, dubbed ‘Axess’.
The first two patients have been...
Registry data highlight long-term trends in haemodialysis access profile of failed...
New findings, recently published in the Journal of Vascular Access (JVA), provide insight into the haemodialysis access profile of failed kidney transplant patients treated in...
Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft
Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a...
Fistula, graft or catheter—first and foremost, dialysis patients want an access...
“Catheters are not nearly as bad as we make them out to be.” This was one of the salient messages delivered by Theodore Saad...
Matteo Tozzi
Having grown up and studied medicine in Rome, Matteo Tozzi is currently deputy head of the Department of Medicine and Surgery, and associate professor...
Pharmacological approaches to reducing arteriovenous fistula failure rates
Sanjay Misra (Rochester, USA) discusses the need for pharmacological approaches that can improve successful, long-term outcomes with arteriovenous fistulas (AVFs) and outlines a handful...
Restorative Axess graft demonstrates promising patency and safety in first-in-human study
The preliminary results from a clinical trial assessing a restorative haemodialysis access graft have shown promising early puncturing, patency and safety data. These findings...
A raft of new directions for vascular access grafts
A departure from the “extreme mantra” of Fistula First unlocks the door to a new, dynamic vision that could swing the pendulum back to...
Xeltis announces “promising outcomes” in restorative graft trials following EU financing
Xeltis has announced promising initial outcomes from two key vascular trials involving its restorative graft technologies.
According to the company, more than 350 successful dialysis...
Precision banding offers “effective, low-morbidity approach” in high-flow haemodialysis accesses
A retrospective review involving nearly 300 patients has concluded that precision banding as a treatment for high-flow haemodialysis accesses offers “an effective, low-morbidity approach”....
Systematic review sheds light on “unpleasant necessity” of cannulation for haemodialysis...
A systematic review published in the Journal of Vascular Access (JVA) has illuminated haemodialysis patients’ views and experiences of arteriovenous access cannulation, concluding that...
InnAVasc gains FDA nod for third study phase of investigational haemodialysis...
As per an announcement on the company’s LinkedIn page, InnAVasc Medical has been granted US Food and Drug Administration (FDA) permission to commence the...
Xeltis initiates European first-in-human trial of restorative haemodialysis access graft
Xeltis has announced initiation of a clinical trial evaluating Axess, which it claims is the first ever restorative synthetic haemodialysis access graft. Several patients...
Amplifi vein dilation system demonstrates “encouraging” clinical results in haemodialysis access
Artio Medical has announced that full results from its first-in-human clinical study of the Amplifi vein dilation system were presented at the 2021 VEITHSymposium...
Bright future for access grafts highlighted at VASBI 2021 with multiple...
New technologies intended to improve the often-mixed outcomes associated with arteriovenous grafts (AVGs) for haemodialysis access were on display at this year’s Vascular Access...
Early data indicate benefits of MAGIC in improving cannulation technique
Early data have indicated that a national project, dubbed MAGIC (Managing access by generating improvements in cannulation), has improved cannulation techniques of haemodialysis accesses...
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
New vascular access handbook intends to provide dialysis patients with answers...
At the 12th Congress of the Vascular Access Society (VAS; 6–9 April 2021, online), Ramon Roca-Tey, senior consultant in nephrology at the Fundación Sanitaria...
PVI 2021: Global standardisation of guidelines and patient-first approach to kidney...
In the future, a global approach to help standardise clinical practice guidelines for kidney disease may be the ideal way forward. This was the...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
VenoStent embarks on clinical trial to improve success rate of vascular...
VenoStent has announced successful enrolment in its initial feasibility clinical trial. The clinical trial is testing the safety and efficacy of its 3D-printed bioabsorbable...
Results from first-in-human study of Amplifi vein dilation system presented at...
Preliminary clinical results from a first-in-human study assessing the Amplifi vein dilation system (Artio Medical) were presented at this year’s Vascular InterVentional Advances conference (VIVA;...
Artio Medical completes enrolment of first-in-human trial investigating Amplifi vein dilation...
Artio Medical announced today it has completed enrolment in its first-in-human study evaluating the Amplifi vein dilation system. In the study, five patients were treated...
Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF
Concept Medical has provided an update on the progress of the IMPRESSION (sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis access dysfunction)...
Nitric oxide, simulation and “living” grafts: Is the landscape of vascular...
The field of vascular access care for haemodialysis patients may look very different in just a few years’ time, with a host of new,...
Early-cannulation grafts display parity with ePTFE options—but also face similar challenges
In addition to demonstrating comparable performance in terms of long-term patency, durability and associated complications, early-cannulation arteriovenous (AV) grafts may hold some advantages when...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
Plastic cannulas offer useful new option in toolbox for renal nurses
Despite currently being less commonly used than metal needles in haemodialysis access, particularly in Europe, plastic cannulas offer a “useful new tool in the...
Clotted haemodialysis accesses can spontaneously recanalise following abandonment
Clotted haemodialysis accesses can spontaneously recanalise following a failed thrombectomy and subsequent abandonment, a retrospective review of 3,137 mechanical thrombectomy procedures has found. The...